Moderna Stock Slides on Citi Downgrade, Patent Lawsuit Setback

Moderna (NASDAQ: MRNA) shares slid nearly 5.9% in pre-market trading after analysts at Citi downgraded the stock, citing significant valuation concerns following a historic rally and pointing to fresh legal risks.

Citi Downgrade Cites Valuation Risk

The primary catalyst for the sell-off was a downgrade to 'Sell' by Citi. In a note to clients, analyst Geoff Meacham wrote that the firm struggles "to justify the valuation through public-company comparisons or pipeline [net present value]."

While Citi raised its price target on Moderna to $80 from a prior $60, the new target still implies a potential downside of roughly 60% from the stock's previous closing price. The move represents a notable shift in institutional consensus, as Moderna previously had only two 'Sell' ratings among approximately two dozen analysts covering the company, according to the source report.

Legal and Market Headwinds

Adding to investor concerns, a Delaware federal court on September 28 denied Moderna’s motion to dismiss a patent infringement lawsuit. The suit, brought by Bayer’s Monsanto division, alleges unauthorized use of mRNA-related intellectual property, introducing a new legal overhang for the company.

Ad

The broader market offered little support for the stock. With the Nasdaq and S&P 500 trading nearly flat, there was no macro tailwind to cushion the company-specific selling pressure.

Context of Recent Rally

The downgrade comes after a period of extraordinary performance for Moderna. The stock had rallied 223% since August 19, a surge sparked by positive late-stage trial results for its personalized cancer vaccine, intismeran autogene, which is being co-developed with Merck (NYSE: MRK).

Following this substantial run-up, the combination of a high-conviction downgrade and unresolved patent litigation has prompted investors to reassess whether the stock's premium valuation can be sustained without more immediate commercial or regulatory catalysts.